Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea...
Capricor Therapeutics, Inc.'s rolling BLA submission of CAP-1002 for the treatment of patients with DMD, expected in Q3 of 2024. Top-line results from Cohort A of the phase 3 HOPE-3 study, using CAP-1...
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR)...
Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024....
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2024 Earnings Call Transcript May 13, 2024 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Kristen Klusk...
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.31 per share a year ago....
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024–...
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024- SAN DIEGO,...
